Table 2.
| Non-HSCT (N=360) | HSCT (N=130) | P-value | ||
|---|---|---|---|---|
| Mean (sd) | Mean (sd) | |||
|
|
||||
| Age | 59.5 (14.5) | 44.4 (14.4) | <0.0001 | |
| 1st CR duration in weeks | 31.1 (39.8) | 41.4 (43.2) | 0.0004 | |
| Delay time in weeks | 15.4 (23.2) | 21.6 (36.6) | <0.0001 | |
| N (%) | N (%) | |||
|
|
||||
| Cytogenetics | Unfavorable | 224 (62.2%) | 66 (50.8%) | |
| Intermediate | 136 (37.8%) | 64 (49.2%) | 0.03 | |
| 1st salvage-induced CR | Non-CR | 293 (81.4%) | 84 (64.6%) | |
| CR | 67 (18.6%) | 46 (35.4%) | 0.0002 | |
*
Wilcoxon test for continuous variables or Fisher exact test for categorical variables
Patient Characteristics according to salvage treatment group. For all evaluable patients treated for relapsed AML statistically significant (P<0.05) differences in age, CR1, and time between 1st salvage and subsequent treatment, proportion of patients with unfavorable cytogenetics, and treatment performed in 1st salvage induced CR were observed between the HSCT cohort and non-HSCT cohorts. These factors were included in the subsequent multiple subgroup analyses.